# AMPLIFY-201 (NCT04853017)

> A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04853017
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Elicio Therapeutics
- Conditions: Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Cholangiocarcinoma; Bile Duct Cancer; Gallbladder Carcinoma
- Interventions: ELI-002 2P
- Enrollment: 25
- Primary outcome: The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 21
- YouTube: 3
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=amplify-201-nct04853017

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04853017", "email": "<work email>"}; the inbox owner confirms by the emailed link.